<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976244</url>
  </required_header>
  <id_info>
    <org_study_id>0118U001612m</org_study_id>
    <nct_id>NCT04976244</nct_id>
  </id_info>
  <brief_title>Brolucizumab for CNV Associated With Pathologic Myopia</brief_title>
  <acronym>COASTUAbaCNV</acronym>
  <official_title>Collaborative Ocular Antiangiogenic Study of Ukraine. Multicentral, Open-label, Randomized, Prospective Study of Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Pathologic Myopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Filatov Institute of Eye Diseases and Tissue Therapy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odessa National Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mykolaiv Region Ophthalmogical Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Polyclinic of Internal Affairs of Ukraine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lesya Ukrainka Volyn National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Filatov Institute of Eye Diseases and Tissue Therapy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of antiangiogenic therapy to&#xD;
      choroidal neovascularization secondary to pathologic myopia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the effectiveness of antiangiogenic therapy to&#xD;
      choroidal neovascularization secondary to pathologic myopia.&#xD;
&#xD;
      This study is planned as a randomized, multicenter, open-label, comperative, interventional.&#xD;
      Patients with myopia included in it will receive brolucizumab or aflibercept.&#xD;
&#xD;
      The treatment proposed in this study is based on the world experience and scientific&#xD;
      developments of the Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of&#xD;
      Ukraine&quot;. Therefore, it is expected that the benefit/risk ratio in relation to the&#xD;
      participation in this study should not be different from that described in the scientific&#xD;
      literature and the benefits outweigh the risk. It is known that the absence of treatment in&#xD;
      these diseases leads to an irreparable loss of central vision.&#xD;
&#xD;
      Patients with a pathologic myopia with CNV (native) will be treated with antiangiogenic drugs&#xD;
      according to the regimen pro re nata.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Chart</measure>
    <time_frame>Baseline-Month 12</time_frame>
    <description>Defined study baseline range of ETDRS equivalent of 20/200 to 20/20) in the study eye; a higher score represents better functioning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT)</measure>
    <time_frame>Baseline-Month 12</time_frame>
    <description>A negative number indicates improvement (reduced thickness).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Number of Intravitreal Injections</measure>
    <time_frame>Baseline-Month 12</time_frame>
    <description>The number of intravitreal injections administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Inflamations after Intravitreal Injections</measure>
    <time_frame>Baseline-Month 12</time_frame>
    <description>The number of inflamations registered in patients after intravitreal injections</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pathologic Myopia</condition>
  <arm_group>
    <arm_group_label>Brolucizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravitreal injection</intervention_name>
    <description>Intravitreal injection to the regimen pro re nata</description>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_label>Brolucizumab</arm_group_label>
    <other_name>Patients after general ophthalmic examination (visometry, refractometry, biomicroscopy, ophthalmoscopy, OCT, FA) receive injections according to the regimen pro re nata from the initial injection.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to read (or, if unable to read due to visual impairment, be read to verbatim by&#xD;
             the person administering the informed consent form or a family member) and understand&#xD;
             the informed consent form and willing to sign the informed consent form.&#xD;
&#xD;
          -  Signed informed consent form.&#xD;
&#xD;
          -  Men and women ≥ 18 years of age.&#xD;
&#xD;
          -  Willing, committed, and able to return for all clinic visits and complete all&#xD;
             study-related procedures.&#xD;
&#xD;
          -  Myopia of greater than or equal to -6 D OR axial length of greater than (if the&#xD;
             spherical myopic equivalent is &lt;6.0 diopters, then the patient should have myopic&#xD;
             changes in the macula: lacquer cracks, focal chorioretinal atrophy, posterior&#xD;
             staphyloma) or equal to 26.5 mm.&#xD;
&#xD;
          -  Active subfoveal or juxtafoveal (within 1 to 199 μm of the center of the fovea) CNV&#xD;
             secondary to pathologic myopia as defined by leakage on FA.&#xD;
&#xD;
          -  Transparent optical media and possibility to mydriasis.&#xD;
&#xD;
          -  Best corrected visual acuity at least 20/200 Equivalent of Snellen (ETDRS).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular media of insufficient quality to obtain fundus and OCT images in the study eye&#xD;
&#xD;
          -  Recurrent mCNV in the study eye&#xD;
&#xD;
          -  History or presence of CNV with an origin other than pathologic myopia in the study&#xD;
             eye&#xD;
&#xD;
          -  Ocular inflammation or external ocular inflammation in the study eye&#xD;
&#xD;
          -  Concurrent disease in the study eye that would compromise BCVA or require medical or&#xD;
             surgical intervention during the study period&#xD;
&#xD;
          -  Any ocular disorder in the study eye that, in the opinion of the investigator, may&#xD;
             confound interpretation of the study results&#xD;
&#xD;
          -  Significant scarring or atrophy in the fovea that indicates substantial irreversible&#xD;
             vision loss in the study eye&#xD;
&#xD;
          -  History of idiopathic or autoimmune-associated uveitis in either eye&#xD;
&#xD;
          -  Evidence at examination of infectious blepharitis, keratitis, scleritis, or&#xD;
             conjunctivitis in either eye or current treatment for serious systemic infection&#xD;
&#xD;
          -  Vitreomacular traction or traction retinal detachment, epiretinal membrane in either&#xD;
             eye&#xD;
&#xD;
          -  Any iris neovascularization and/or vitreous hemorrhage in either eye&#xD;
&#xD;
          -  Uncontrolled glaucoma, or previous filtration surgery in either eye&#xD;
&#xD;
          -  Prior and concomitant treatments&#xD;
&#xD;
          -  Any prior or concomitant treatment with another investigational agent for mCNV in the&#xD;
             study eye.&#xD;
&#xD;
          -  Any previous panretinal photocoagulation or subfoveal thermal laser therapy in the&#xD;
             study eye.&#xD;
&#xD;
          -  Any prior treatment with photodynamic therapy in the study eye.&#xD;
&#xD;
          -  Cataract surgery within 3 months prior to Day 1 in the study eye.&#xD;
&#xD;
          -  Yttrium-aluminum-garnet laser capsulotomy within 2 months prior to Day 1 in the study&#xD;
             eye.&#xD;
&#xD;
          -  Any other intraocular surgery within 3 months prior to Day 1 in the study eye.&#xD;
&#xD;
          -  History of vitreoretinal surgery and/or scleral buckle surgery in the study eye.&#xD;
&#xD;
          -  Any prior treatment with anti-VEGF agents&#xD;
&#xD;
          -  Previous use of intraocular or periocular corticosteroids in either eye within 3&#xD;
             months prior to Day 1&#xD;
&#xD;
          -  Previous assignment to treatment during this study&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  History of cerebrovascular disease or myocardial infarction within 6 months prior to&#xD;
             Baseline/Day 1&#xD;
&#xD;
          -  History of other disease, metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug, may affect interpretation of the&#xD;
             results of the study, or renders the subject at high risk from treatment complications&#xD;
&#xD;
          -  Women of childbearing potential without contraception, women who intend to breastfeed&#xD;
             during the study. All subjects (both men and women) of childbearing potential who are&#xD;
             unwilling to use adequate birth control measures during the course of the study.&#xD;
&#xD;
          -  Renal failure requiring dialysis or renal transplant&#xD;
&#xD;
          -  Participation in an investigational study within 30 days prior to Screening/Visit 1&#xD;
             that involved treatment with any drug (excluding vitamins and minerals) or device&#xD;
&#xD;
          -  Known serious allergy to the fluorescein sodium for injection in angiography or&#xD;
             Verteporfin&#xD;
&#xD;
          -  Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrii MD Korol, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Filatov Institute of Eye Diseases and Tissue Therapy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrii MD Korol, PhD</last_name>
    <phone>+380936327266</phone>
    <email>andrii.r.korol@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olha MD Pohosian</last_name>
    <phone>+380932084927</phone>
    <email>olha.a.pohosian@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lesya Ukrainka Volyn National University</name>
      <address>
        <city>Lutsk</city>
        <zip>43025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadiia MD Ulianova, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mykolaiv Region Ophthalmogical Hospital</name>
      <address>
        <city>Mykolaiv</city>
        <zip>54000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krasymira MD Rylkovа, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odessa National Medical University</name>
      <address>
        <city>Odesa</city>
        <zip>65028</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadiia MD Ulianova, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Filatov Institute of Eye Diseases and Tissue Therapy</name>
      <address>
        <city>Odesa</city>
        <zip>65061</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <reference>
    <citation>Korol AR, Zadorozhnyy OS, Naumenko VO, Kustryn TB, Pasyechnikova NV. Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study. Clin Ophthalmol. 2016 Nov 4;10:2223-2229. eCollection 2016.</citation>
    <PMID>27853350</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Filatov Institute of Eye Diseases and Tissue Therapy</investigator_affiliation>
    <investigator_full_name>Andrii Korol, MD, PhD</investigator_full_name>
    <investigator_title>Head of Laser Department</investigator_title>
  </responsible_party>
  <keyword>fundus diseases</keyword>
  <keyword>antiangiogenic therapy</keyword>
  <keyword>choroidal neovascularization</keyword>
  <keyword>pathologyc myopia</keyword>
  <keyword>intravitreal injection</keyword>
  <keyword>anti-VEGF</keyword>
  <keyword>brolucizumab</keyword>
  <keyword>aflibercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

